Pathology Analysis & Statistics in the United Kingdom, September 2014

You might be interested in: cancer, breast cancer, leukemia, more »

1-50 of about 2 400 reports

Purchase Reports From Reputable Market Research Publishers

EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023

EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • July 2014
  • by Global Data

EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023 Summary Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences ...

  • Industries : Pathology
  • Countries : Germany, World, United States, Spain, United Kingdom, Italy, France, Japan
Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Brilinta (Acute Coronary Syndrome) - Forecast and ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Effient (Acute Coronary Syndrome) - Forecast and ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Crestor (Acute Coronary Syndrome) - Forecast and ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, United States, United Kingdom, Europe
Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Xarelto (Acute Coronary Syndrome) - Forecast and ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Angiomax (Acute Coronary Syndrome) - Forecast and ...

  • Industries : Pathology
  • Countries : World, United States, Spain, Italy, France, Germany, Japan, United Kingdom, Europe
Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Cangrelor (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, United States, United Kingdom, Europe
Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Zontivity (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Alirocumab (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Evolocumab (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Bococizumab (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Anacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Anacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Anacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Anacetrapib (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Evacetrapib (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
EU5 Hernia Repair Market Outlook to 2020

EU5 Hernia Repair Market Outlook to 2020

  • $ 3 000
  • Industry report
  • July 2014
  • by Global Data

EU5 Hernia Repair Market Outlook to 2020 Summary GlobalData's new report, "EU5 Hernia Repair Market Outlook to 2020", provides key market data on the EU5 Hernia Repair market. The report provides value, ...

  • Industries : Pathology
  • Countries : United Kingdom, Spain, Italy, France, Germany, Europe
United Kingdom Hernia Repair Market Outlook to 2020

United Kingdom Hernia Repair Market Outlook to 2020

  • $ 2 500
  • Industry report
  • July 2014
  • by Global Data

United Kingdom Hernia Repair Market Outlook to 2020 Summary GlobalData's new report, "United Kingdom Hernia Repair Market Outlook to 2020", provides key market data on the United Kingdom Hernia Repai ...

  • Industries : Pathology
  • Countries : United Kingdom
Brinzolamide  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Brinzolamide - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Duloxetine  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Duloxetine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States
Sildenafil  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Sildenafil - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Sitagliptin  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Sitagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States
Temsirolimus  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Temsirolimus - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Donepezil  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Donepezil - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Irbesartan  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Irbesartan - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Rivastigmine  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Rivastigmine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Ropinirole  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Ropinirole - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Valsartan  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Valsartan - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Dasatinib  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Dasatinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Erlotinib  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Erlotinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Gefitinib  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Gefitinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Lapatinib  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Lapatinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Rivaroxaban  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Rivaroxaban - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States
About 4 000 reports

Download Unlimited Documents from Trusted Public Sources

Global Pathology Description

  • Flu Express
  • September 2014
    4 pages
  • Influenza  

  • World  

    United Kingdom  

    China  

View report >

Uk - Country Risk

September 2014

Nickel Markets In The Uk

September 2014

2 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

Johnson and Johnson

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.